Effect of prostaglandin analogues on tear proteomics and expression of cytokines and matrix metalloproteinases in the conjunctiva and cornea

Experimental Eye Research

Volumn 94, Issue 1, 2012, Pages 13-21

  Lopilly Park, Hae Young ^a   Kim, Jie Hyun ^a   Lee, Kyung Min ^a   Park, Chan Kee ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Cornea; Cytokine; Matrix metalloproteinase; Prostaglandin; Tear

Indexed keywords

BIMATOPROST; COLLAGEN TYPE 1; CYTOKINE; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LATANOPROST; MATRIX METALLOPROTEINASE; MESSENGER RNA; PROSTAGLANDIN DERIVATIVE; STROMELYSIN; TIMOLOL; TIMOLOL MALEATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRAVOPROST;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRADFORD ASSAY; CLINICAL ARTICLE; CONJUNCTIVA; CONJUNCTIVA EPITHELIUM; CONJUNCTIVAL EPITHELIAL CELL; CONTROLLED STUDY; CORNEA; CORNEA STROMA; CORNEA THICKNESS; CYTOKINE PRODUCTION; CYTOLOGY; DRUG EFFECT; EYE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LOW TENSION GLAUCOMA; MALE; MICROCIRCULATION; NONHUMAN; OPEN ANGLE GLAUCOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; RABBIT; TEAR FILM; WESTERN BLOTTING;

ADMINISTRATION, TOPICAL; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CONJUNCTIVA; CORNEA; CYTOKINES; EPITHELIUM, CORNEAL; EYE PROTEINS; FEMALE; GLAUCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; PROTEOMICS; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TEARS;

EID: 84855846700     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.10.017     Document Type: Article

References (34)

1. Amano S., Nakai Y., et al. Acase of keratoconus progression associated with the use of topical latanoprost. Jpn. J. Ophthalmol. 2008, 52(4):334-336.
2. BenEzra D., Foidart J.M. Collagens and non collagenous proteins in the human eye. I. corneal stroma invivo and keratocyte production invitro. Curr. Eye Res. 1981, 1(2):101-110.
3. Bergonzi C., Giani A., et al. Evaluation of prostaglandin analogue effects on corneal keratocyte density using scanning laser confocal microscopy. J.Glaucoma 2010, 19(9):617-621.
4. Bito L.Z. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv. Ophthalmol. 1997, 41(Suppl. 2):S1-14.
5. Bito L.Z., Camras C.B., et al. "The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals. Prog. Clin. Biol. Res. 1989, 312:349-368.
6. Brandt J.D., Gordon M.O., et al. Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology 2008, 115(9):1550-1556.
7. Cho H.I., Covington H.I., et al. Immunolocalization of type VI collagen in developing and healing rabbit cornea. Invest. Ophthalmol. Vis. Sci. 1990, 31(6):1096-1102.
8. Clark A.F. New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest. Ophthalmol. Vis. Sci. 1998, 39(13):2514-2516.
9. Di Girolamo N., Wakefield D., et al. Differential expression of matrix metalloproteinases and their tissue inhibitors at the advancing pterygium head. Invest. Ophthalmol. Vis. Sci. 2000, 41(13):4142-4149.
10. Gaton D.D., Sagara T., et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch. Ophthalmol. 2001, 119(8):1165-1170.
11. Grierson I., Jonsson M., et al. Latanoprost and pigmentation. Jpn. J. Ophthalmol. 2004, 48(6):602-612.
12. Honda N., Miyai T., et al. Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch. Ophthalmol. 2010, 128(4):466-471.
13. Kamiya K., Aizawa D., et al. Effects of antiglaucoma drugs on refractive outcomes in eyes with myopic regression after laser in situ keratomileusis. Am. J. Ophthalmol. 2008, 145(2):233-238.
14. Kon C.H., Occleston N.L., et al. "A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 1998, 39(8):1524-1529.
15. Lee A.J., Goldberg I. Emerging drugs for ocular hypertension. Expert Opin. Emerg. Drugs 2011, 16(1):137-161.
16. Lee R.E., Davison P.F. The collagens of the developing bovine cornea. Exp. Eye Res. 1984, 39(5):639-652.
17. Lindsey J.D., Kashiwagi K., et al. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr. Eye Res. 1996, 15(8):869-875.
18. Mietz H., Esser J.M., et al. Latanoprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both invitro and invivo. Invest. Ophthalmol. Vis. Sci. 2003, 44(12):5182-5188.
19. Moore B.A., Aznavoorian S., et al. Induction of collagenase-3 (MMP-13) in rheumatoid arthritis synovial fibroblasts. Biochim. Biophys. Acta 2000, 1502(2):307-318.
20. Nowroozzadeh M.H. Prostaglandin analogs may aggravate myopic regression after laser in situ keratomileusis. Am. J. Ophthalmol. 2009, 147(4). 754; author reply 754-755.
21. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. a study on cultured cells and tissue sections. Exp. Eye Res. 1998, 67(2):179-191.
22. Oh D.J., Martin J.L., et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest. Ophthalmol. Vis. Sci. 2006, 47(3):953-963.
23. Oh D.J., Martin J.L., et al. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 2006, 47(9):3887-3895.
24. Ooi Y.H., Oh D.J., et al. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 2009, 50(11):5259-5265.
25. Parrish R.K., Palmberg P., et al. Acomparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. 2003, 135(5):688-703.
26. Sagara T., Gaton D.D., et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol. 1999, 117(6):794-801.
27. Shapiro S.D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 1998, 10(5):602-608.
28. Tamiya S., Wormstone I.M., et al. Induction of matrix metalloproteinases 2 and 9 following stress to the lens. Exp. Eye Res. 2000, 71(6):591-597.
29. Wang X., Li K.F., et al. "Matrix metalloproteinase inhibitors: a review on bioanalytical methods, pharmacokinetics and metabolism. Curr. Drug Metab. 2011, 12(4):395-410.
30. Weinreb R.N., Kashiwagi K., et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 1997, 38(13):2772-2780.
31. Welsh C., Gay S., et al. Collagen heterogeneity in normal rabbit cornea. I. isolation and biochemical characterization of the genetically-distinct collagens. Biochim. Biophys. Acta 1980, 625(1):78-88.
32. Wu K.Y., Wang H.Z., Hong S.J. Effect of latanoprost on cultured porcine corneal stromal cells. Curr. Eye. Res. 2005, 30. 871-379.
33. Ye H.Q., Maeda M., et al. Differential expression of MT1-MMP (MMP-14) and collagenase III (MMP-13) genes in normal and wounded rat corneas. Invest. Ophthalmol. Vis. Sci. 2000, 41(10):2894-2899.
34. Zhong Y., Shen X., et al. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. Cornea 2011.